首页> 外文期刊>Molecular medicine reports >Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells
【24h】

Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells

机译:Suberoylanilide异羟肟酸可通过逆转草酸铂诱导的胃癌细胞Src活化来增强草酸铂的抗肿瘤活性

获取原文
获取原文并翻译 | 示例
           

摘要

Oxaliplatin and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA), also known as vorinostat, are potent antitumor agents. The aim of this study was to investigate the effect of SAHA on the antitumor efficacy of oxaliplatin in gastric cancer and the interaction between oxaliplatin and SAHA. Cell growth inhibition was evaluated using Cell Counting Kit-8 and colony formation assays. Xenografts established in nude mice were used to assess tumor growth in vivo. Western blot analysis was used to detect the expression of acetyl-histone H3, phosphorylated histone H2AX (gamma H2AX), B-cell lymphoma 2 (Bcl-2), cleaved caspase-3, cleaved poly (ADP-ribose) polymerase (PARP), phosphorylated- (p-) Src, Src, Akt and p-Akt in gastric cancer cells. The in vitro growth of SGC-7901, Hs746T and MKN28 gastric cancer cells was found to be dose-dependently inhibited by oxaliplatin and SAHA. Furthermore, combined treatment was observed to be more effective in inhibiting cancer cell growth and colony formation than monotherapy. Similar effects were found in the xenografts. A positive interaction was identified between oxaliplatin and SAHA (between-subject effects of oxaliplatin and SAHA, P<0.001). In addition, combined exposure to oxaliplatin and SAHA increased gamma H2AX expression and decreased Bc1-2 expression. The expression of cleaved caspase-3 and PARP was also increased with combination treatment. Oxaliplatin-induced Src phosphorylation was detected in gastric cancer cells, as we have previously reported. However, this effect was inhibited by SAHA. The oxaliplatin-induced Src phosphorylation was not impaired with Akt inhibition. In conclusion, oxaliplatin and SAHA exhibited a positive interaction when used in combination and were found to suppress gastric cancer cell survival and growth. The reversal of oxaliplatin-induced Src activation may be responsible for this positive interaction.
机译:奥沙利铂和组蛋白脱乙酰基酶抑制剂辛二酰苯胺异羟肟酸(SAHA),也称为伏立诺他,是有效的抗肿瘤药。本研究的目的是研究SAHA对奥沙利铂在胃癌中的抗肿瘤作用以及奥沙利铂和SAHA之间的相互作用。使用Cell Counting Kit-8和集落形成测定法评估细胞生长抑制。在裸鼠中建立的异种移植物用于评估体内肿瘤的生长。 Western印迹分析用于检测乙酰组蛋白H3,磷酸化组蛋白H2AX(γH2AX),B细胞淋巴瘤2(Bcl-2),裂解的caspase-3,裂解的聚(ADP-核糖)聚合酶(PARP)的表达,胃癌细胞中的磷酸化(p-)Src,Src,Akt和p-Akt。发现SGC-7901,Hs746T和MKN28胃癌细胞的体外生长受到奥沙利铂和SAHA剂量依赖性抑制。此外,观察到联合治疗比单药治疗在抑制癌细胞生长和集落形成方面更有效。在异种移植物中发现了类似的效果。在奥沙利铂和SAHA之间鉴定出正相互作用(奥沙利铂和SAHA在受试者之间的作用,P <0.001)。此外,联合暴露于奥沙利铂和SAHA可增加γH2AX表达并降低Bc1-2表达。联合处理还增加了裂解的caspase-3和PARP的表达。如我们先前报道,在胃癌细胞中检测到奥沙利铂诱导的Src磷酸化。然而,该作用被SAHA抑制。奥沙利铂诱导的Src磷酸化未因Akt抑制而受损。总之,奥沙利铂和SAHA组合使用时表现出正相互作用,并被发现抑制胃癌细胞的存活和生长。奥沙利铂诱导的Src激活的逆转可能是这种积极相互作用的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号